-
Amjin's layoff sales team expands its business layout in the Chinese market
Time of Update: 2021-02-24
/>, for example, we want to continue to use digital capabilities to reach customers and conduct clinical trials around the world faster, with greater efficiency and efficiency. " chief executive, Robert Bradway, said by phone. expanding its
-
To ling pharmaceutical industry won the "2020 Chinese medicine heritage innovation enterprise"
Time of Update: 2021-02-24
, of which 8 are listed in the national health insurance directory, 5 are national base drug species. Among them, lianhua Qing plague, heart contact, ginseng heart capsule three varieties of annual sales of more than 1 billion yuan, even
-
40% of Sanofi's market is in a hurry? Sichuan pharmaceutical companies have entered the market with more than 1 billion anti-epileptic injections
Time of Update: 2021-02-11
Pharmaceuticals sodium valium acetate injection with a thick solution to imitate the 3 categories of applications submitted for listing in the review and approval (in the drug review center). meters of intranet data show that in 2018, China's
-
The chairman of China Pharmaceuticals, a well-known pharmaceutical company, resigned
Time of Update: 2021-02-11
, the controlling shareholder is China General Technology (Group) Holdings Co., Ltd., with a registered capital of 1.068 billion yuan, and is one of the three major central enterprises with the pharmaceutical industry as its main business. <br
-
Ering Pharmaceuticals: Let the party flag fly high on the front line of supply protection
Time of Update: 2021-02-10
and his wife abounded on the production line of Lianhua Qing plague capsules. , director of the three workshops of preparations, as an old party member, led more than 800 employees, make concerted efforts, strict quality control, pay attention
-
Hesco will take $2.8 billion
Time of Update: 2021-02-04
difficide, both highly effective antiretroviral drugs. as a single tablet, enqutabinofovir tablets have the characteristics of simplified treatment, remarkable efficacy, high patient compliance with drug administration, low drug resistance
-
Koren added another imitation! 10 intestinal nutrition drugs
Time of Update: 2021-02-02
compound amino acid (15AA-I)/glucose electrolyte injection for the domestic first imitation, omega-3 fish oil / long-chain fat emulsion for the second domestic.
-
Beda Pharmaceuticals to issue "H shares"
Time of Update: 2021-02-01
A few days ago, Beda Pharmaceuticals announced that the company has considered the adoption of the "on the company's H-share issue and listing on the main board of the Stock Exchange of Hong Kong Limited" bill. founded in 2003 to develop
-
Dongsong medicine and a new class of drugs hit the impact of a surge of 900% insulin
Time of Update: 2021-01-30
selective PI3K pyrethroid inhibitors intended for the treatment of blood tumors, HEC122505 MSOH tablets as neurological drugs, have been initiated phase I clinically, and toluene sulfonate nigtini capsules and hydrochloric acid ivenione tablets have
-
Well-known pharmaceutical companies to abolish the sales team
Time of Update: 2021-01-30
that at present, many pharmaceutical companies are exploring other channels besides public hospitals, including but not limited to retail terminals, private hospitals, online markets and so on. But it must be seen that, in addition to a small number
-
Hunan pharmaceutical companies took more than 8 billion oral anti-sugar drugs, the original research drugs were again affected
Time of Update: 2021-01-30
Medicine Network January 22 - January 21, the Official Website of the State Drug Administration shows that Hunan Qianjin Xiangjiang Pharmaceutical's Akapo sugar tablets to copy 4 categories of products were approved, and as reviewed.
-
The Roche Tecentriq/Avastin combination improves the overall survival of hepatocellular carcinoma
Time of Update: 2021-01-25
with the initial analysis and support the combination therapy for the treatment of patients with hepatocellular carcinoma. the safety of Tecentriq and Avastin combination therapies is consistent with the known safety of each drug, and no new adverse events occur.
-
CRO track all-line surge Tag Pharmaceuticals, Kanglong into a 10% rise in the rise and stop of new drugs
Time of Update: 2021-01-25
in the 1970s, the early CRO companies in the form of public or private research institutions, small, only for pharmaceutical companies to provide limited drug analysis services. beginning in the 1980s, as the FDA's drug regulations continued to improve
-
To Ling Pharmaceutical Lianhua Qing plague capsules to obtain the Mongolian drug registration approval
Time of Update: 2021-01-25
announcement, Lianhua Qing plague products have been repeatedly included in the National Health And Health Commission, the State Administration of Traditional Chinese Medicine cold, influenza-related disease diagnosis and treatment program.
-
What's so special about the layout of the research and development pipeline for the old drivers of pharmaceutical companies?
Time of Update: 2021-01-25
Romosozumab Drug Overview Source: Pharmaceutical Intelligence Data Pipeline Source: Amjin's official website Romosozumab currently has four listings, 82 clinical trials, eight of which were released in the last year, and the drug's sales figures for 2019 are 238.257 million yuan.
-
Charles River Laboratory has collaborated with Driv Bio to expand biology
Time of Update: 2021-01-25
On January 14, 2020, Charles River Laboratories (NYSE: CRL) announced that it has entered into a strategic partnership with JADE Biomedical, an end-to-end quality management service provider for the biopharmaceutical industry. partnership
-
Hepple intends to transfer Kymab's stake, which was acquired by Sanofi
Time of Update: 2021-01-25
FP BV, a wholly owned subsidiary of Sanofi, signed an equity transfer agreement with all Kymab shareholders, including Hong Kong-based Hepple, to take a full stake in Kymab.
-
The application for clinical trial of the MCLA-129 injectable drug from Beda Pharmaceuticals was accepted
Time of Update: 2021-01-25
MCLA-129 is expected to effectively address EGFR inhibitor resistance caused by a variety of mechanisms, especially c-Met amplification or over-expression, with the potential to provide benefits to patients with drug-resistant NSCLC.
-
3.5 billion injection varieties Hengrui will take the first imitation
Time of Update: 2021-01-24
4 enterprises, such as Hengrui Pharmaceuticals, Colum Pharmaceuticals, Vit Pharmaceuticals and Yangzijiang Pharmaceutical Group, submitted applications for the listing of sodium chloride injections of right metomide hydrochloride according to the imitation 3 categories.
-
Micro-invased medical split, the latest news announced
Time of Update: 2021-01-24
Pharmaceutical Network January 14 - Micro-invased medical robots to be listed January 12, according to China Electronic News, Shanghai minimally invascope medical robots (Group) Co., Ltd. has signed a listing counseling agreement with COFCO, the proposed listing of the board.
